Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PCNA | P12004 | 1/20 | 0.36 |
| ▸ | LIG1 | P18858 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192820 | 1.00 | DPP4 (0.48) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL6747617 | 0.98 | DPP4 (0.47) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4668650 | 0.85 | DPP4 (0.46) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6194940 | 0.81 | TAAR1 (0.52) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4202520 | 0.80 | SLC6A4 (0.47) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL6195390 | 0.79 | TAAR1 (0.50) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2032547 | 0.78 | DPP4 (0.57) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2029984 | 0.78 | DPP4 (0.57) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2029981 | 0.78 | DPP4 (0.57) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5516728 | 0.78 | MME (0.43) | DPP4TAAR1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HEINE NIKLAS | 2010-07-01 | — | — | US | disclosed |
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HEINE NIKLAS | 2010-07-01 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2007017510-A2 | ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | DPP4 3357/4885TAAR1 134/4885SLC1A3 64/4885 |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | DPP4 2388/4885TAAR1 4634/4885SLC1A3 3254/4885 |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | DPP4 3281/4885TAAR1 136/4885SLC1A3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.